Cue Biopharma, Inc. (CUE) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 25.87 |
| Open | 26 |
| Day High | 26.03 |
| Day Low | 24.6 |
| 52-Week High | 45.5 |
| 52-Week Low | 4.97 |
| Volume | 182,539 |
| Average Volume | 266,377 |
| Market Cap | 183.43M |
| PE | -0.93 |
| EPS | -27.02 |
| Moving Average 50 Days | 28.89 |
| Moving Average 200 Days | 20.05 |
| Change | -0.62 |
Cue Biopharma to Present New In vitro Data for CUE-401 at the 20th World Immune Regulation Meeting (WIRM) 2026
GlobeNewswire Inc.
Mar 09, 2026 12:00 PM GMT
BOSTON, March 09, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment
Cue Biopharma Announces Preclinical Safety and Tolerability Data for CUE-401 for the Treatment of Autoimmune and Inflammatory Diseases
GlobeNewswire Inc.
Feb 17, 2026 1:00 PM GMT
In two non-GLP studies, CUE-401 was well tolerated with no adverse events observed Proof-of-concept studies reinforce promising preclinical profile and therapeutic potential of CUE-401 BOSTON, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma
Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Financial and Business Officer
GlobeNewswire Inc.
Feb 12, 2026 1:00 PM GMT
BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment